| Name | Title | Contact Details |
|---|
Welcome to your destination. Our mission is simple: to provide the best for your pet.
Biodex Medical Systems, Inc. is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. Biodex Medical Systems, Inc. is based in Shirley, NY. You can find more information on Biodex Medical Systems, Inc. at www.biodex.com
St Lukes House Inc is a Bethesda, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
We`re on a mission to make life better for patients taking part in clinical trials around the world, and their caregivers. Our solutions focus on the four key elements of a successful clinical trial: recruitment, engagement, retention and trial outcomes. Combining our in-house technology platforms with 24/7 truly personalised patient care, we focus on creating remarkable patient experiences at every stage of the clinical journey. Remarkable means going above and beyond to support patients in a way that works best for them and their lives. Whether that`s facilitating clinical trial participation in their own homes, supporting them to travel safely to and from study sites, or using technology to manage everything from expense reimbursement to telehealth, we work with our partners to support the protocol design that meets their patient`s needs. Understanding the complexities of the patient journey is paramount to advancing medicine, and exploring digital technology that enables better trial outcomes has never been more important. This all starts with putting patients first in clinical research. When you partner with us, your patients receive a truly remarkable service and your trial outcomes are better.
Relmada Therapeutics (OTCQB: RLMD) is a clinical-stage, publicly traded specialty pharmaceutical company developing novel versions of proven drug products together with new chemical entities that potentially address areas of high unmet medical need in the treatment of chronic pain. Relmada has a diversified portfolio of four lead products at various stages of development including d-Methadone (REL-1017) its N-methyl-D-aspartate (NMDA) receptor antagonist for neuropathic pain; topical mepivacaine (REL-1021), its orphan drug designated topical formulation of the local anesthetic mepivacaine; oral buprenorphine (REL-1028) its oral dosage form of the opioid analgesic buprenorphine; and LevoCap ER (REL-1015), its abuse resistant, sustained release dosage form of the opioid analgesic levorphanol. Relmada`s product development efforts are guided by the internationally recognized scientific expertise of our research team. Relmada`s approach is expected to reduce clinical development risks and costs while potentially delivering valuable products in areas of high unmet medical needs.